Immuron Ltd ADR (IMRN)

Jan 17, 2025, 6:00 AM EST - 19 hours ago

Immuron Travelan® continued strong sales growth

Jan 15, 2025, 6:00 AM EST - 2 days ago

Immuron Announces New Research Collaboration targeting Antimicrobial Resistance

Jan 14, 2025, 6:00 AM EST - 3 days ago

Immuron Announces Travelan® Clinical Trial Update

Dec 2, 2024, 6:00 AM EST - 6 weeks ago

Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th

Nov 21, 2024, 6:33 PM EST - 2 months ago

Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event

Nov 18, 2024, 8:30 AM EST - 2 months ago

Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event

Oct 16, 2024, 6:00 AM EDT - 3 months ago

Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference

Oct 4, 2024, 6:30 AM EDT - 3 months ago

NMRC Reports Results for Campylobacter Controlled Human Infection Model Study

Sep 19, 2024, 9:42 AM EDT - 4 months ago

Traveler's Diarrhea Therapeutics Pipeline Market Report 2024 Featuring Immuron, Scandinavian Biopharma, and Sigmoid Pharma

Sep 5, 2024, 11:54 AM EDT - 4 months ago

Immuron Plans Phase 2 Trial for IMM-529 following FDA review

Aug 20, 2024, 7:00 AM EDT - 5 months ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA CVKD ELUT EUDA GDTC GOSS GOVX

Aug 16, 2024, 6:00 AM EDT - 5 months ago

Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®

Aug 15, 2024, 6:14 PM EDT - 5 months ago

Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference

Aug 7, 2024, 6:00 AM EDT - 5 months ago

Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect

Jul 2, 2024, 6:00 AM EDT - 7 months ago

Immuron requests pre-IND meeting for IMM-529 with FDA filing

May 31, 2024, 6:00 AM EDT - 8 months ago

Immuron Board Changes

May 31, 2024, 6:00 AM EDT - 8 months ago

Immuron CEO Steven Lydeamore to present at Peak Sky High

May 7, 2024, 6:00 AM EDT - 9 months ago

Immuron Limited to Present at the Emerging Growth Conference

May 3, 2024, 6:00 AM EDT - 9 months ago

Immuron Director Resignation

Apr 15, 2024, 6:00 AM EDT - 9 months ago

Immuron to host Live Virtual Event

Apr 10, 2024, 6:00 AM EDT - 10 months ago

Immuron Travelan® sales continued strong growth

Mar 7, 2024, 6:00 AM EST - 11 months ago

Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US

Feb 21, 2024, 6:00 AM EST - 11 months ago

Immuron Presentation Australian Biologics Festival 2024

Feb 13, 2024, 6:00 AM EST - 1 year ago

Immuron achieves record Travelan® sales

Feb 8, 2024, 6:00 AM EST - 1 year ago

Immuron CEO, Steven Lydeamore Investor Webinar Presentation

Jan 16, 2024, 6:00 AM EST - 1 year ago

Immuron achieves record half yearly Travelan® sales

Dec 22, 2023, 6:00 AM EST - 1 year ago

Immuron Clinical Trials Update

Dec 4, 2023, 6:00 AM EST - 1 year ago

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Nov 13, 2023, 6:00 PM EST - 1 year ago

Immuron CEO Steven Lydeamore Investor Webinar Presentation

Oct 30, 2023, 7:21 AM EDT - 1 year ago

Immuron CEO Steven Lydeamore presented at AusBioInvest

Oct 18, 2023, 6:00 AM EDT - 1 year ago

Immuron Announces Travelan® Clinical Study Cohort 2 commences

Oct 11, 2023, 6:00 AM EDT - 1 year ago

Immuron achieves record quarterly Travelan® sales

Sep 18, 2023, 7:30 AM EDT - 1 year ago

Immuron Limited Announces Participation in the LD Micro Main Event XVI

Sep 13, 2023, 6:00 AM EDT - 1 year ago

Immuron achieves record monthly Travelan® sales

Sep 11, 2023, 6:00 AM EDT - 1 year ago

Immuron CEO, Steven Lydeamore to present at H.C. Wainwright

Aug 14, 2023, 6:00 AM EDT - 1 year ago

Immuron to present at the Military Health System Research Symposium

Jul 25, 2023, 6:00 AM EDT - 1 year ago

Immuron Announces First Patients Enrolled in Travelan® Clinical Study

Jul 24, 2023, 6:00 AM EDT - 1 year ago

Immuron CEO, Steven Lydeamore to present at Bioshares

Jul 11, 2023, 6:00 AM EDT - 1 year ago

Immuron Business Update - Ateria Health launches Juvia™ in Australia

Jul 5, 2023, 6:00 AM EDT - 1 year ago

Immuron FY23 Sales increase 136% on FY22 Sales

Jun 30, 2023, 6:00 AM EDT - 1 year ago

Immuron Chairman Transition

Jun 22, 2023, 6:00 AM EDT - 1 year ago

Immuron Business Update: Letter to Shareholders

May 30, 2023, 6:00 AM EDT - 1 year ago

Immuron Initiates Recruitment of Travelan® Clinical Study

May 16, 2023, 7:30 AM EDT - 1 year ago

Immuron Limited Announces Participation in the LD Micro Invitational XIII

May 8, 2023, 6:35 AM EDT - 1 year ago

Immuron stock rockets after FDA removes hold on IND of infectious diarrhea treatment

May 8, 2023, 6:00 AM EDT - 1 year ago

Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial Initiation

May 2, 2023, 6:00 AM EDT - 1 year ago

Immuron CEO, Steven Lydeamore to present at Coffee Microcaps

Apr 19, 2023, 6:00 AM EDT - 1 year ago

Immuron Q3 FY23 Business Update Presentation

Apr 11, 2023, 6:00 AM EDT - 1 year ago

Q3 FY23 Business Update Webinar Notification

Apr 6, 2023, 6:00 AM EDT - 1 year ago

Immuron Q3 Sales reach 150% of 1H Sales